期刊
ULTRASOUND IN MEDICINE AND BIOLOGY
卷 44, 期 6, 页码 1155-1163出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ultrasmedbio.2018.01.001
关键词
Atherosclerosis; Contrast-enhanced ultrasound; Microbubbles; Molecular Imaging
资金
- National Institutes of Health (NIH), Bethesda, Maryland [SBIR-HHSN26820140045 C]
- NIH [R01-HL078610, R01-HL111969, R01-HL120046]
- National Space Biomedical Research Institute (National Aeronautics and Space Administration) [14 NSBRI1-0025]
- Swiss National Science Foundation
The aim of this study was to evaluate a panel of endothelium-targeted microbubble (MB) ultrasound contrast agents bearing small peptide ligands as a human-ready approach for molecular imaging of markers of high-risk atherosclerotic plaque. Small peptide ligands with established affinity for human P-selectin, VCAM-1, LOX-1 and von Willebrand factor (VWF) were conjugated to the surface of lipid-stabilized MBs. Contrast-enhanced ultrasound (CEUS) molecular imaging of the thoracic aorta was performed in wild-type and genetargeted mice with advanced atherosclerosis (DKO). Histology was performed on carotid endarterectomy samples from patients undergoing surgery for unstable atherosclerosis to assess target expression in humans. In DKO mice, CEUS signal for all four targeted MBs was significantly higher than that for control MBs, and was three to sevenfold higher than in wild-type mice, with the highest signal achieved for VCAM-1 and VWF. All molecular targets were present on the patient plaque surface but expression was greatest for VCAM-1 and VWF. We conclude that ultrasound contrast agents bearing small peptide ligands feasible for human use can be targeted against endothelial cell adhesion molecules for inflammatory cells and platelets for imaging advanced atherosclerotic disease. (C) 2018 Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据